A5036808328- CAR-T cell therapy research
- Cancer Research and Treatments
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Viral Infectious Diseases and Gene Expression in Insects
- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Glaucoma and retinal disorders
- Colorectal Cancer Treatments and Studies
- Metabolism, Diabetes, and Cancer
- Drug-Induced Hepatotoxicity and Protection
- Sarcoma Diagnosis and Treatment
- Retinal Imaging and Analysis
- Pharmacological Effects and Toxicity Studies
Copenhagen University Hospital
2022-2025
Herlev Hospital
2022-2023
University of Copenhagen
2018
Rigshospitalet
2017
LTX-315 is an oncolytic peptide that elicits both local and systemic immune responses upon intratumoral injection. In the present pilot trial, we treated patients with metastatic soft tissue sarcoma combination of adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes. Six heavily pretreated were included trial which four proceeded to therapy. Overall, treatment was considered safe only expected manageable toxicity. The best overall clinical response stable disease...
In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared ipilimumab improved progression-free survival patients unresectable stage IIIC-IV after failure of first-line or second-line treatment. Based on this trial, we cost-utility analysis. A Markov decision model was constructed to estimate expected costs (expressed 2021€)...
To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines. Retrospective cohort study 566 eyes centre-involved DME who started intravitreal treatment between January 2011 December 2013 Greater Copenhagen region. Data were retrieved from a database patient records March 2016 analysed...
Highlights•TILT-123 plus TILs mediate complete remission in a patient with mucosal melanoma.•Tumor biopsies revealed increased infiltration of CD4+ and CD8+ T cells.•Indications clinical efficacy TILT-123 alone were observed.•The combination is promising new treatment modality.AbstractBackgroundDespite significant advancements the malignant melanoma, metastatic melanoma remains therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, limited response...
Abstract Background A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) a chimeric adenovirus suitable intravenous (i.v.) delivery due to its capsid modification and dual selectivity devices. It armed with tumor necrosis alpha interleukin-2 promoting T-cell activation lymphocyte trafficking tumors, thereby enhancing the antitumor immune response. Here, we present findings...
Abstract Background Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk muscle pain (myalgia) type 2 diabetes. However, underlying mechanisms remain disputed. Methods We investigated whether statin induced myalgia is coupled impaired glucose homeostasis using oral tolerance test (OGTT), intravenous (IVGTT), hyperinsulinemic euglycemic clamp. performed a cross‐sectional study users...
11567 Background: Adoptive cell transfer (ACT) with tumor-infiltrating lymphocytes (TILs) is a potent treatment that can induce complete and durable tumor regression as documented in patients metastatic melanoma. To our knowledge, ACT has not been utilized for soft-tissue sarcoma (STS). LTX-315 an oncolytic peptide shown to increase TILs malignant tumors after intratumoral injection. In this trial, were treated the combination of TIL - based ACT. Methods: Patients progressive STS minimum one...
2658 Background: Immune checkpoint inhibitors provide limited benefit in patients with immunologically cold tumors, characterized by a lack of T cells. This creates niche for cell-inducing agents such as TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFa-IRES-hIL2). While the 5/3 chimeric oncolytic adenovirus platform prompts potent immunogenic capacity per se, this virus has been armed TNFa and IL-2 selected based on their ability to activate attract cells into tumors. capsid...
<h3>Background</h3> The deployment of immunotherapies in the forefront cancer therapy fundamentally changed patient care and understanding tumor immunology. In contrast to more conventional therapies, immune checkpoint inhibitors (ICIs) adoptive cell therapies (ACTs), are characterized by durable responses treatment metastatic cancer. However, such clinical benefits account only for a portion treated patients, leaving room improvement or generation new immunotherapy strategies. TILT-123...
<div>Abstract<p>After a positive phase III trial, it is evident that treatment with tumor-infiltrating lymphocytes (TIL) safe, feasible, and effective modality for patients metastatic melanoma. Further, the safe feasible in diverse solid tumors, regardless of histologic type. Still, TIL has not obtained regulatory approvals to be implemented on larger scale. Therefore, its availability currently restricted few centers worldwide. In this review, we present current knowledge...
Tumor Infiltrating Lymphocyte (TIL) therapy has recently proved effective in patients with metastatic melanoma. Oncolytic adenovirus TILT-123 (igrelimogene litadenorepvec) is armed tumor necrosis factor-alpha and interleukin-2 which were selected specifically for their ability to enhance TIL cytotoxicity without the need preconditioning chemotherapy or postconditioning IL2. In a phase I, open-label, 3+3 dose-escalating multicenter trial, stage IV melanoma treated multiple intravenous...
<div>Abstract<p>After a positive phase III trial, it is evident that treatment with tumor-infiltrating lymphocytes (TIL) safe, feasible, and effective modality for patients metastatic melanoma. Further, the safe feasible in diverse solid tumors, regardless of histologic type. Still, TIL has not obtained regulatory approvals to be implemented on larger scale. Therefore, its availability currently restricted few centers worldwide. In this review, we present current knowledge...
<h3>Background</h3> After the first Immune Checkpoint Inhibitor (ICI) was approved (ipilimumab, 2011 for cancer therapy, list of indications routinely treated with ICIs keeps increasing. In this new era immunotherapy, major drawback approach is difficulty in delivering long term benefits to a larger portion patients. Different forms immunotherapy used solid tumor patients seem work better immunologically hot tumors. To that extent, TILT-123 (an Oncolytic Adenovirus armed TNFa and IL-2)...